Coronavirus update Sales and regulatory update

Paris, France and Camberley, UK – 2 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division. http://novacyt.com/wp-content/uploads/2020/06/Novacyt-COVID-19-update-02-06-20-ENGLISH.pdf

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

Paris, France and Camberley, UK – 1 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised in

Visit Page

Director/PDMR Shareholdings

Paris, France and Camberley, UK – 26 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 May 2020, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”): http://novacyt.com/wp-content/uploads/2020/05/Novacyt-Directors-Dealings-ENGLISH-26.05.2020.pdf

Visit Page